CAR-T Ed ForumCAR-T and CLL: A Patient and Caregiver Journey Recorded Wednesday, April 21, 2021 https://youtu.be/-2duh-jA3ZU Continue to Session 2: Immunotherapy: A New Paradigm for Treatment CLL Society Resources Download Slides
CAR-T Ed Forum: Welcome and Introductions Recorded Wednesday, April 21, 2021 https://youtu.be/JcQzgxI8ga0 Continue to Session 1: CAR-T and CLL: A Patient and Caregiver Journey CLL Society Resources Download Slides CAR-T Webpage
Dr. Utkarsh H. Acharya, DO, FACP took great care of me during my CAR-T therapy as an outpatient at the Seattle Cancer Care Alliance (SCCA)/HUTCH and as an inpatient twice at
Brian posts on his CAR-T blog and the grief and joy in the CLL world. Also more on swimming.
I want to introduce a remarkable young physician who you will be hearing more from in the future. Dr. Utkarsh H. Acharya, DO, FACP is now the Program Director, Hematology-Oncology Fellowship
Take Away Points: As the CAR-T technology improves, new targets for many cancers are being researched and identified. When the re-infused T cells recognize our cancer, they activate and release large
Take Away Points: CAR-T (Chimeric Antigen Receptor T-cell) is a cellular immune therapy using our own T cells that have been educated to recognize and attack our cancer. The target of
Following discontinuation of a non-covalent Bruton tyrosine kinase inhibitor (BTKi), venetoclax is clinically active in patients with CLL or Richter transformation who have not received it in the past. CAR-T therapy may also be an option, but this requires further study.
Join CLL Society and PeerView Institute to learn updates on the latest CLL data from a panel of experts including Drs. Anthony Mato, Nicole Lamanna, Matthew Davids, and Catherine Coombs and gain their insight into the practicalities of therapeutic planning, including safety considerations associated with BTKi, PI3Ki, BCL-2i, and CAR-T therapy.
